Bank of Nova Scotia
CTMX icon

Bank of Nova Scotia’s CytomX Therapeutics CTMX Stock Holding History

Bank of Nova Scotia’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-13,661
Closed -$58.2K – 1119
2025
Q4 		$58.2K Buy
+13,661
New +$51.9K ﹤0.01% 1073

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bank of Nova Scotia's CTMX Position: Q1 2026 in Review

Bank of Nova Scotia sold out of CytomX Therapeutics (CTMX) in Q1 2026, closing a stake of 13,661 shares — an estimated $58.2K sold.

Bank of Nova Scotia first reported a position in CTMX in Q4 2025 and held it in 1 quarter. The position peaked at $58.2K in Q4 2025. 179 funds tracked by Wall St. Rank hold CTMX as of Q1 2026.

  • Bank of Nova Scotia reported no remaining CytomX Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of Nova Scotia sold 13,661 CytomX Therapeutics shares in Q1 2026, an estimated $58.2K.
  • Bank of Nova Scotia first reported a position in CytomX Therapeutics in Q4 2025 and held it in 1 quarter.
  • Bank of Nova Scotia's CytomX Therapeutics position peaked at $58.2K in Q4 2025.
  • 179 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2026.

Based on Bank of Nova Scotia's 13F filing for Q1 2026, filed 14 May 2026.